Here's Why Grail Stock Bounced Back 16% Today
Key Points
Follow-up data could make the trial's findings look much better than they do now.
Management believes the results of the trial won't impact an approval decision by the Food and Drug Administration (FDA)
- 10 stocks we like better than Grail ›
Grail (NASDAQ: GRAL) stock rose by more than 16% by midday. The move follows a couple of days of brutal declines after the release of top-line results from its three-year, 142,000-person trial of its Galleri multi-cancer early detection (MCED) test with England's National Health Service.
What went wrong for Grail
I discussed the stock's decline on the first day of trading after the release, and the market punished it again on Monday. However, let's focus on why the market may be optimistic about future developments.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
As a reminder, the primary endpoint of the trial (which it missed) was to achieve a statistical significant reduction in combined Stage III and Stage IV cancers across 12 deadly indications.
Image source: Getty Images.
The test itself won't reduce cancer, but if the Galleri test is working in the early stages, a given population treated after relatively early stage detection will see fewer late-stage detections. Unfortunately, the trial did not demonstrate a statistically meaningful reduction in Stage III and Stage IV (combined) detection in the tested group compared to the control group.
CEO Bob Ragusa argued on the earnings call that "we don't think that this finding is going to impact the approvability of Galleri with the FDA." Still, insurers might not be willing to pay for a test that doesn't meet its primary endpoint.
Where next for Grail
The main hope, noted by an analyst on the earnings call, is that the 6-month to 12-month follow-up data (Grail is extending the trial) will "prove out" the study. Ragusa acknowledged that "we probably should have allowed for a longer follow-up period."
It can do so in two main ways. First, unfortunately, the control group could see growth in cancer. Second, the high incidence of cancers detected at Stage III in the tested group can be treated, leading to an even bigger reduction in Stage IV detection.
While predicting this probability is complicated, it's not zero. Especially, as President Joshua Ofman argued that the trial did show "the ability to shift the stage at diagnosis for the population in a randomized clinical trial."
Should you buy stock in Grail right now?
Before you buy stock in Grail, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Grail wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,174,241!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 24, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.
Recommended Articles
